Research Desk Line-up: FutureFuel Post Earnings Coverage
LONDON, UK / ACCESSWIRE / August 17, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Ashland Global Holdings Inc. (NYSE: ASH), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=ASH, following the Company's reporting of its third quarter fiscal 2017 operating results on August 01, 2017. The basic materials Company outperformed top- and bottom-line expectations. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member's account at:
Get more of our free earnings reports coverage from other constituents of the Chemicals - Major Diversified industry. Pro-TD has currently selected FutureFuel Corp. (NYSE: FF) for due-diligence and potential coverage as the Company announced on August 09, 2017, its financial results for Q2 and six-month 2017 which ended on June 30, 2017. Register for a free membership today, and be among the early birds that get access to our report on FutureFuel when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on ASH; also brushing on FF. With the links below you can directly download the report of your stock of interest free of charge at:
For the quarter ended June 30, 2017, Ashland reported a loss from continuing operations of $16 million on sales of $870 million. For Q3 FY16, the Company reported earnings from continuing operations of $24 million on sales of $790 million.
On an adjusted basis, the Company's income from continuing operations attributable to Ashland was $0.83 per diluted share in Q3 FY17 versus $0.78 per diluted share for Q3 FY16. Ashland's revenue and earnings numbers topped analysts' consensus estimates of $842.78 million and $0.70 per share, respectively.
Ashland's Segment Performance
Specialty Ingredients - During Q3 FY17, the Specialty Ingredients business reported sales of $591 million, up 7% on a y-o-y basis. The Company noted that approximately six percentage points of this increase was driven by the successful completion of the Pharmachem's acquisition. With the addition of approximately $7 million of EBITDA from Pharmachem in the reported quarter, total adjusted EBITDA grew 2% to $131 million on a y-o-y basis, at the upper end of the Company's outlook range.
For Q3 FY17, the segment's Consumer Specialties sales and volumes grew by 16% and 11%, respectively on a y-o-y basis. Ashland's personal care team reported a strong quarter, led by disciplined volume and price execution within the oral and skin care end markets. Industrial Specialties' sales grew by 1% and volumes declined by 1% on a y-o-y basis.
For Q4 FY17, Specialty Ingredients' sales are expected to be in the range of $590 million-$610 million compared to $532 million in Q4 FY16. The segment's adjusted EBITDA is expected to be in the range of $135 million-$145 million versus $126 million in the prior year's same period. Also during the quarter, y-o-y price increases are expected to be greater than y-o-y raw material cost increases.
Composites - During Q3 FY17, the Composites segment's sales surged 20% to $209 million on a y-o-y basis, driven by a 10% increase in volumes resulting from strong demand for the Company's value-added products in North America and Asia, as well as the addition of volumes from the facility in Etain, France, that Ashland recently acquired from Reichhold. Ashland noted that the Etain facility contributed approximately three percentage points to the sales increase with a small EBITDA contribution. Composites reported adjusted EBITDA of $27 million, reflecting a growth of 17% on a y-o-y basis.
For Q4 FY17, Composites expects sales to be in the range of $200 million-$210 million, reflecting continued volume growth, disciplined pricing, and a full-quarter contribution from the Etain composites facility compared to $162 million in the year-ago same quarter. Adjusted EBITDA is expected to be in the range of $20 million-$25 million compared to $14 million in Q4 FY16.
Intermediates and Solvents (I&S) – the I&S division reported sales of $70 million for Q3 FY17, reflecting a 9% gain on a y-o-y basis, driven by the successful implementation of price increases for butanediol (BDO), consistent with improving global supply-demand dynamics. During the reported quarter, I&S reported adjusted EBITDA of $10 million, a 43% on a y-o-y basis.
For Q4 FY17, I&S expects sales to be in the range of $75 million-$85 million, reflecting continued mix and price improvements, compared to $60 million in Q4 FY16. Adjusted EBITDA is expected to be in the range of $10 million-$15 million compared to $3 million in the year earlier corresponding quarter.
During Q3 FY17, Ashland's capital expenditures were $53 million compared to $61 million in Q3 FY16. The Company generated free cash flow of $79 million during the reported quarter compared to $27 million in the prior year's same quarter. For FY17, Ashland is forecasting free cash flow in the range of $90 million to $100 million. At the quarter end, Ashland had approximately $1.1 billion of available liquidity, including $492 million in cash. The majority of this cash is held outside the US.
On Wednesday, August 16, 2017, the stock closed the trading session at $61.56, slightly up 0.67% from its previous closing price of $61.15. A total volume of 735.71 thousand shares have exchanged hands. Ashland Global's stock price advanced 4.17% in the past six months and 10.27% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have rallied 15.13%. The stock has a dividend yield of 1.46%. At Wednesday's closing price, the stock's net capitalization stands at $3.86 billion.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily